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Purpose: Myocilin (MYOC) mutations are associated with primary open-angle glaucoma (POAG) in multiple populations.
Here we examined the role of MYOC mutations in a black South African population with primary open-angle glaucoma
(POAG).
Methods: Unrelated black South African subjects with POAG and unaffected controls were recruited from the St. John
Eye Hospital (Soweto, Johannesburg, South Africa) and East London Hospital Complex (Eastern Cape, South Africa). A
complete eye examination including visual field assessment was performed in all subjects. Blood samples were obtained
for DNA extraction. The complete coding region of MYOC was sequenced using the PCR-based Sanger method. Identified
mutations were compared to known MYOC mutations.
Results: One hundred-thirteen POAG cases and 131 controls were recruited for analysis. A total of 19 variants were
observed. Probable glaucoma-causing mutations were observed in 4.4% of POAG cases. A previously reported glaucoma-
causing mutation, Tyr453MetfsX11, was observed in three cases and one control. Two other sequence variants, Gly374Val
and Lys500Arg, occurred only in cases. Other sequence variants, including 6 novel variants, occurred in at least one
control.
Conclusions: A small minority of black South Africans with POAG carry MYOC mutations. The Gly374Val mutation
might represent a novel glaucoma-causing mutation. The Tyr453MetFSX11 mutation appears to be a glaucoma-causing
mutation with incomplete penetrance.
Glaucoma is a group of disorders that cause progressive
loss of retinal ganglion cells, optic nerve cupping, and visual
field  loss.  It  is  the  most  common  cause  of  irreversible
blindness worldwide [1]. Of glaucoma’s multiple sub-types,
the most common is primary open-angle glaucoma (POAG)
[1,2]. POAG is currently responsible for an estimated 3.3
million cases of bilateral blindness worldwide [3]. POAG
treatment  is  currently  limited  to  modification  of  elevated
intraocular  pressure  (IOP),  an  established  risk  factor.  A
greater  understanding  of  other  risk  factors  and  molecular
mechanisms will likely improve treatment and detection [2].
Genetic risk factors are known to contribute to POAG as
first-degree relatives of affected individuals are 3–9 fold more
likely to develop the disease [4]. Identification of genetic risk
factors  could  greatly  improve  detection  and  treatment  of
POAG. However, POAG has a complex inheritance pattern
that confounds many approaches used to study Mendelian
traits. Only a small proportion of POAG cases have been
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traced to mutations in individual genes. Instead, the majority
of POAG cases appear to be influenced or caused by multiple
genetic factors [4]. To date, 15 POAG-associated loci have
been identified [4]. Within these loci several genes have been
identified including myocilin (MYOC) [5], optineurin [6], WD
repeat-containing protein 36 (WDR36) [7], and cytochrome
p450 1B1 [8]. Among these genes, MYOC has been found to
harbor  more  glaucoma-causing  mutations  than  any  other
identified risk gene [4].
The role of MYOC in POAG was first identified through
genetic linkage analysis of families carrying juvenile-onset
forms of POAG [5,9]. In these families, MYOC mutations
were  found  to  associate  with  glaucoma  phenotypes
characterized by: 1) juvenile or early-age onset (<40 years);
2)  high  intraocular  pressure;  and  3)  autosomal  dominant
inheritance. Some MYOC mutations are associated with adult-
onset (>40 years) POAG and appear responsible for 3%–5%
of cases worldwide [2]. Over 70 unique mutations have been
identified [10], with many of these mutations being specific
to a single population or ethnic group [11].
Given that many MYOC mutations are found only in a
single population, it is useful to screen MYOC in multiple
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1064populations. For example, a previous screen of 90 POAG
cases from Ghana West-Africa yielded two novel glaucoma-
causing  mutations  that  have  not  been  reported  in  any
Caucasians  cases  [12].  At  present,  work  in  numerous
populations  has  led  to  a  large  catalog  of  mutations.  This
catalog is useful for genetic screening, especially for first-
degree relatives of individuals with POAG [10]. The catalog
also  provides  targets  for  functional  studies  with  mutant
MYOC protein. Previous studies have suggested that MYOC
mutations alter the solubility of MYOC protein [13,14] and
disrupt its secretion [15-18]. These studies have benefitted
from  the  growing  assortment  of  mutations  observed  in
humans. Future studies will likely benefit from identifying
additional MYOC mutations.
Novel  MYOC  mutations  will  likely  be  found  in  sub-
Saharan Africa populations. There is more genetic diversity
within Africa than anywhere else on Earth [19]. Current data
on sub-Saharan Africa is limited to two studies that focused
on West Africans. The first was conducted on a Ghanaian
cohort in West Africa [12]. The second was conducted on an
African American cohort [20], the majority of which were
likely of West African ancestry [21]. No studies have been
reported in East or South African populations. Here we report
the first mutation screen of MYOC in black South Africans
with POAG. Our study can help to establish the contribution
of MYOC mutations to POAG in this population. It also can
help identify novel mutations for future functional work and
genetic screening.
METHODS
Study participants: This study adhered to the tenets of the
Declaration of Helsinki. The research protocol was approved
by all participating universities including the University of the
Witwatersrand  Human  Research  Ethics  Committee  and
Stellenbosch University Health Research Ethics Committee.
Southern African black participants with clinically diagnosed
POAG and unaffected southern African control subjects were
recruited  from  the  St.  John  Eye  Hospital  in  Soweto
(Johannesburg,  South  Africa)  and  East  London  Hospital
Complex  (Eastern  Cape,  South  Africa).  Written  informed
consent was obtained from all participants. Ethnic affiliation
was established by the home language of participants and that
of their parents and grandparents. All participants underwent
a  standardized  detailed  ophthalmic  examination  by  an
ophthalmologist  (S.E.I.W.  or  R.R.).  The  examination
included  measurement  of  intraocular  pressure  (IOP)  by
applanation,  slit  lamp  biomicroscopy,  gonioscopy,  dilated
pupil examination of the lens and fundus, and visual field
testing. Subjects with POAG had evidence of glaucomatous
optic neuropathy and visual field loss with open angles on
gonioscopy and no evidence for a secondary cause for the
glaucoma.  Gender-  and  ethnicity-matched  South  African
subjects  with  normal  anterior  segment  and  optic  nerve
examination and an IOP of less than 21 mmHg were recruited
as control subjects. Control subjects were selected to be older
than POAG participants to ensure that a diagnosis of POAG
could be excluded in the controls.
DNA sequencing analysis:   Genomic  DNA  was   extracted
using standard methodology [22]. Briefly, blood was obtained
using  peripheral  venipuncture.  The  blood  was  anticoagu-
lated  and lysed.  Cellular  protein  was salted out of solution
using  NaCl.  Genomic  DNA, still  in solution, was removed,
precipitated  in  ethanol,  and  resuspended  in  water. Primers
flanking the entire coding sequence of MYOC    were designed   
with  Primer3  software [23].  Primer sequences are provided
in  Table  1. The targeted region covered  at least 80 base pairs
into  each  intron  to  screen  for  potential mutations affecting 
exon  splicing.  Platinum Taq DNA polymerase (Invitrogen,
Carlsbad,  CA) was used for all the polymerase-chain react-
ions  (PCR).  The  PCR  amplifications  were  performed  in
ThermoHybaid  MBS   02,  02S,   and  02G  PCR   machines 
(Thermo  Scientific, Waltham, MA).   Completed PCR react-
ions  were  purified and sequenced  in the forward  direction
using BigDye chemistry (Applied Biosystems, Foster City,
CA).   All  the   sequences  were   analyzed  using   the
Sequencher 4.9 software package (Gene Codes,  Ann  Arbor,
MI). Potential mutations were  confirmed  by repeating PCR
amplification with the relevant sample  and  then sequencing
in the reverse direction.
Statistical analysis: The Fisher’s exact test was used to test
the association of variant alleles with POAG. The exact test
was  also  used  to  examine  Hardy–Weinberg  equilibrium
(HWE) for the observed variants.
RESULTS
Subject demographics are summarized in Table 2. Briefly,
there were 113 POAG cases and 131 control subjects in the
study data set. POAG cases had a mean age of 59.6±12.7
years. Controls had a mean age of 70.5±8.7 years. Study
subjects were self-identified as black South Africans. Subjects
spoke  a  range  of  southern  Bantu  languages  including
IsiXhosa,  IsiZulu,  Setswana,  Sesotho,  Sepedi,  Xitsonga,
Tshivenda,  Siswati,  and  IsiNdebele.  The  distribution  of
languages was similar in cases and controls.
A  total  of  19  MYOC  variants  were  observed  in  the
sampled population. All variants were in HWE (p>0.05). Of
the 19 variants, 12 occurred in coding regions, including 7
silent changes, 4 missense changes, and 1 frameshift change
(Table 3). Two of these changes appeared to be associated
with glaucoma. Tyr453MetfsX11, a frameshift mutation, was
observed in 3 POAG cases and 1 control. It was previously
reported as a glaucoma-causing mutation [20]. Gly374Val, a
novel missense mutation, was observed in two cases and no
controls.  Neither  mutation  appeared  to  cause  a  clinically
distinguishable form of glaucoma when compared to cases
that did not carry mutations in MYOC. In all, 4.4% of black
South African cases carried one of these probable mutations.
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associated  with  glaucoma.  The  three  variants  were
Lys500Arg,  Arg76Lys,  and  Glu352Lys.  The  Lys500Arg
substitution has been previously reported and is considered
neutral [20]. Here it was observed in 2 cases and no controls.
The Arg76Lys substitution has been reported as neutral [20].
We found this variant in no cases and 1 control. Finally, the
Glu352Lys substitution has unknown pathogenicity [20,24,
25]. We found Glu352Lys in 5 cases and 5 controls.
We identified 14 silent variants in this South African
population that were predicted to not impact the amino acid
sequence of MYOC. Of these, 7 were synonymous variants in
the MYOC coding region (Table 3). The other 7 were in
intronic or promoter regions (Table 4). All 14 were observed
in at least one control. None had been previously reported as
glaucoma-causing  [20,26].  Among  these  variants,  one
significant  association  was  observed  (p<0.05).  The  non-
coding variant c.731–73C>T was more common in controls
(9.9%) than in cases (1.8%). This variant was observed in 4
tribal  groups  and  was  not  significantly  over-  or
underrepresented in any one group (p>0.05).
The  interaction  of  multiple  variants  within  MYOC
appeared to be an unlikely cause of glaucoma in our cases.
Only one person was found to carry multiple nonsynonymous
variants.  This  individual  carried  Tyr453MetfsX11  and
Glu352Lys. The individual had glaucoma, but so did two other
participants  that  carried  only  Tyr453MetfsX11.  All  other
individuals  had  no  more  than  1  nonsynonymous  coding
variant. Multiple synonymous and non-coding mutations did
occur  together  frequently.  However,  patterns  of  linkage
disequilibrium among these variants were consistent between
cases and controls.
DISCUSSION
This study represents the first screen for MYOC mutations in
black  South  Africans.  We  observed  probable  glaucoma-
causing mutations in 4.4% of individuals with POAG. This
frequency is consistent with previously reported African and
non-African cohorts with POAG [2]. Importantly, seven novel
variants  were  observed  including  a  missense  mutation,
Gly374Val, that was found only in cases.
The  novel  missense  mutation  Gly374Val  was  only
observed in cases and appears to cause glaucoma. It occurred
TABLE 1. LIST OF PCR PRIMERS FOR MYOC (MYOCILIN) EXON SEQUENCING IN BLACK SOUTH AFRICAN INDIVIDUALS.
Myocilin
exon




Exon1a ATCTTGCTGGCAGCGTGAA TCTCTGGTTTGGGTTTCC 614 chr1:171,621,342–
171,621,955
Exon1b GACAGCTCAGCTCAGGAAGG GAAGGTGATCGCTGTGCTTT 663 chr1:171,620,991–
171,621,653
Exon2 AGCAAAGACAGGGTTTCACC AGGGCTTTGTTAGGGAAAGG 554 chr1:171,607,517–
171,608,071
Exon3a CCCAGACGATTTGTCTCCAG TCCCAGGTTTGTTCGAGTTC 648 chr1:171,605,327–
171,605,974
Exon3b GAGAAGGAAATCCCTGGAGC TGGTGACCATGTTCATCCTTC 598 chr1:171,604,914–
171,605,511
               The covered genomic regions were based on the February 2009 human reference sequence (GRCh37).
TABLE 2. DEMOGRAPHICS OF STUDY SUBJECTS.
Demographic Control POAG
Age at recruitment 70.5 ± 8.7   59.6 ± 12.7  
Sex
Male 57 44% 55 49%
Female 74 56% 58 51%
Tribal affiliation
IsiXhosa 40 31% 23 20%
IsiZulu 37 28% 41 36%
Setswana 19 15% 15 13%
Sesotho 13 10% 12 11%
Sepedi 6 5% 14 12%
Xitsonga 6 5% 3 3%
Tshivenda 3 2% 3 3%
Siswati 3 2% 1 1%
Isindebele 2 2% 0 0%
Other 2 2% 1 1%
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1066in two affected heterozygotes. It was absent in 131 controls.
Also, it is predicted to be damaging to the MYOC protein by
SIFT [27] and PolyPhen [28]. These lines of evidence suggest
that Gly374Val causes POAG.
One other variant, Lys500Arg, was found exclusively in
cases. It was observed in two POAG cases that were both
heterozygous.  Both  cases  were  also  heterozygous  for  a
synonymous  variant,  Glu396Glu,  but  carried  no  other
variants. Previous evidence regarding the Lys500Arg variant
is mixed. Lys500Arg has been observed in POAG-affected
individuals in several populations and has not been reported
in a control sample [20]. However, it was observed in one
sample from the general population by Fingert et al. [20].
Functional predictions on Lys500Arg are conflicting. One
group predicted that the Lys500Arg substitution might have
structural  consequences  similar  to  Ile499Phe  [29],  a
glaucoma-causing  mutation  [30].  However,  Polyphen  and
SIFT predict Lys500Arg to be tolerated and Ile499Phe to be
possibly damaging [27,28]. Lys500Arg is of interest given its
close proximity to a cryptic peroxisomal-targeting motif that
has been implicated in the pathogenesis of MYOC-associated
glaucoma  [18].  More  evidence  is  needed  to  establish  if
Lys500Arg contributes to glaucoma.
The  Tyr453MetfsX11  mutation  was  observed  at  a
relatively  high  rate  in  South  Africans  compared  with
previously reported populations. It was observed in 2.6% of
South African cases (n=113). For comparison, it was observed
in 0.3% of African American cases (n=312) [20], and no
Ghanaian cases from West Africa (n=90) [12]. This sequence
variant has not been reported in any non-African populations.
This study was the first to find Tyr453MetfsX11 in a
control. The one unaffected carrier was an 80 year old female
with no evidence of glaucoma. Given the identification of an
unaffected carrier, the Tyr453MetfsX11 mutation might be
pathogenic  but  incompletely  penetrant.  Incomplete
penetrance has been observed for other known glaucoma-
causing  mutations  such  as  Gln368stop  in  Caucasian
populations and Arg46stop in Asian populations [11]. Like
TABLE 3. LIST OF CODING VARIANTS IDENTIFIED FROM MYOC EXON SEQUENCING IN BLACK SOUTH AFRICAN INDIVIDUALS WITH OR WITHOUT POAG.
Nucleotide
sequence change*






c.1357delT Tyr453MetfsX11 - Glaucoma-Causing
[20]
3 (2.7%) 1 (0.8%)
c.654G>A Glu218Glu - Novel 2 (1.8%) 3 (2.3%)
c.1121G>T Gly374Val - Novel 2 (1.8%) 0 (0.0%)
c.1054G>A Glu352Lys rs61745146 Uncertain [20,24,25] 5 (4.4%) 5 (3.8%)
c.39T>G Pro13Pro rs12082573 Neutral [20] 8 (7.1%) 10 (7.6%)
c.227G>A Arg76Lys rs2234926 Neutral [20] 0 (0.0%) 1 (0.8%)
c.477A>G Leu159Leu rs61730977 Neutral [20] 7 (6.2%) 9 (6.9%)
c.612G>T Thr204Thr rs57824969 Neutral [20] 5 (4.4%) 3 (2.3%)
c.975G>A Thr325Thr rs61730976 Neutral [20] 14 (12.4%) 6 (4.6%)
c.1041T>C Tyr347Tyr rs61730974 Neutral [20] 0 (0.0%) 1 (0.8%)
c.1188G>A Glu396Glu rs61730975 Neutral [20] 9 (8.0%) 7 (5.3%)
c.1499A>G Lys500Arg - Neutral [20]‡ 2 (1.8%) 0 (0.0%)
            *Nucleotides numbered as in Ensembl accession number ENSG00000034971 (transcript ENST00000037502). ‡See text.
TABLE 4. LIST OF NON-CODING VARIANTS IDENTIFIED FROM MYOC EXON SEQUENCING IN BLACK SOUTH AFRICAN INDIVIDUALS









c.-92_-91delCT - Novel 1 (0.9%) 2 (1.5%)
c.604+13A>C - Novel 7 (6.2%) 6 (4.6%)
c.604+50G>A - Novel 7 (6.2%) 9 (6.9%)
c.731–73C>T rs79255460 Novel 2 (1.8%) 13 (9.9%)
c.731–23G>A - Novel 2 (1.8%) 1 (0.8%)
c.-83G>A rs2075648 Neutral [13] 0 (0.0%) 1 (0.8%)
c.730+35A>G rs2032555 Neutral [19] 10 (8.8%) 21 (16.0%)
        *Nucleotides numbered as in Ensembl accession number ENSG00000034971 (transcript ENST00000037502) referenced to the
        February 2009 human reference sequence (GRCh37).
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1067these  mutations,  Tyr453MetfsX11  truncates  the  MYOC
protein; however, it is a frameshift mutation that results in the
addition of 10 ectopic amino acids. Only a small number of
frameshift mutations have been reported to date, and these
have been strongly associated with glaucoma [10].
The Glu352Lys variant was also highly represented in
this  group  of  black  South  Africans  compared  with  other
populations. We observed the variant in 4.4% of our cases and
3.8% of our controls. By comparison, Glu352Lys has been
reported at frequencies of 0.6% in African American (n=312)
cases and 0.1% in Caucasian cases (n=727) [20]. These low
frequencies in other populations have made classification of
the  Glu352Lys  variant  difficult  [20,24,25].  However,
Glu352Lys appears to be benign in black South Africans as it
was observed in several controls. This result is consistent with
a previous functional study that found Glu352Lys did not alter
MYOC  protein  solubility  like  some  known  pathogenic
mutations [13].
It is not clear why an intronic variant, c.731–73C>T, was
overrepresented  in  the  controls.  One  possibility  was  the
variant  could  be  overrepresented  in  IsiXhosa-speaking
subjects, who constituted 31% of control subjects compared
to  only  20%  of  POAG  subjects  (Table  2).  However,  the
IsiXhosa controls carried the variant at a similar frequency
(10%) as the total control frequency (9.9%) for this variant.
To our knowledge, this variant has not been reported in any
previous studies of MYOC. It is listed in the dbSNP database
as rs79255460. While it is conceivable that the variant could
protect against POAG, it is important to note that a Bonferroni
correction would have eliminated significance. Replication of
our result would warrant further study of rs79255460.
One  challenge  with  studying  POAG  in  black  South
Africans is the low rate of diagnosis within this population. A
previous study found that, among an urban subpopulation of
black adults, only 13% of POAG cases had been diagnosed
[31]. The low rate of diagnosis causes problems for both
personal disease history and family history. Reported family
histories are likely to include many false negatives due to
undiagnosed family members. In our study, only one carrier
of a MYOC mutation claimed to have a parent with glaucoma.
The lack of family members with glaucoma may result from
historically  low  rates  of  diagnosis  among  black  South
Africans.
Our  results  agree  with  previous  work  that  suggests
MYOC  is  not  related  to  population  differences  in  POAG
prevalence [20]. Black South Africans, like other African
groups, have a high rate of POAG compared to Caucasians
[31-34].  However,  black  South  Africans  did  not  have  a
correspondingly high rate of MYOC mutations in this study.
Based on this result, it appears that MYOC mutations are not
responsible  for  increased  levels  of  POAG  in  black  South
Africans. This result is consistent with previous work with
African populations [12,20].
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